Enterprise Value
-2.948M
Cash
10.16M
Avg Qtr Burn
-5.076M
Short % of Float
5.24%
Insider Ownership
7.04%
Institutional Own.
33.04%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Cancer, Lymphoma, Leukemia | Phase 1/2 Data readout | |
Oral Plogosertib Details Solid tumor/s, Lymphoma | Phase 1 Data readout |